AAPG vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
AAPG's Piotroski F-Score of 4/9 indicates weak financial health, with no Altman Z-Score available to assess bankruptcy risk. The company exhibits severe profitability issues, with a negative profit margin of -296.77% and ROE of -159.65%, alongside a 71.6% YoY revenue decline. Despite a high gross margin of 90.87%, the business is not generating sustainable earnings. The stock trades at a premium valuation (Price/Book: 79.25) with no intrinsic value or Graham Number, suggesting speculative pricing. Analysts rate it a 'strong_buy' with a target of $49.14, but this is not supported by fundamentals.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
AAPG vs MRK: Head-to-Head Comparison
This page compares Ascentage Pharma Group Internat (AAPG) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.